Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study

Background Follicular lymphoma (FL) and marginal zone lymphoma (MZL) are indolent non‐Hodgkin lymphomas (iNHL). Median survival for iNHL is approximately 20 years. Because standard treatments are not curative, patients often receive multiple lines of therapy with associated toxicity—rationally desig...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer 2024-03, Vol.130 (6), p.876-885
Hauptverfasser:	Gordon, Max J., Feng, Lei, Strati, Paolo, Lee, Hun Ju, Hagemeister, Fredrick B., Westin, Jason R., Samaniego, Felipe, Marques‐Piubelli, Mario L., Vega Vazquez, Francisco, Parra Cuentas, Edwin R., Solis‐Soto, Luisa M., Ma, Wencai, Wang, Jing, Claret, Linda, Averill, Barbara, Ibanez, Karina, Fayad, Luis E., Flowers, Christopher R., Green, Michael R., Davis, R. Eric, Neelapu, Sattva S., Fowler, Nathan H., Nastoupil, Loretta J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adenine - analogs & derivatives Antineoplastic Combined Chemotherapy Protocols - adverse effects Exanthema Exanthema - chemically induced Exanthema - drug therapy Humans Immunomodulation Immunotherapy indolent lymphoma Kinases Labels Lenalidomide - therapeutic use Lymphoma Lymphoma, B-Cell, Marginal Zone - drug therapy Lymphoma, Follicular - drug therapy Lymphoma, Follicular - pathology non‐Hodgkin lymphoma (NHL) Piperidines Rituximab Survival Targeted cancer therapy targeted therapy Toxicity Tyrosine
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!